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Protein kinase C isoform θ (PKCθ) is a key modulator ofTCR signaling and mediates activa-
tion of NF-κB, NF-AT, and AP-1 transcription factors. Although in vitro studies of PKCθ−/−
T cells have shown impaired activation responses, in vivo studies indicate that PKCθ require-
ment is not universal. While PKCθ is important in induction of experimentally induced
autoimmune diseases in mice and generation of Th2 responses, it is not essential for
induction of T cell proliferative and cytotoxic responses against inﬂuenza virus, LCMV, and
vaccinia virus. The context-speciﬁc involvement of PKCθ in T cell responses suggests that
inhibition of PKCθmay be beneﬁcial in some but not all situations. In the bonemarrow trans-
plantation (BMT) setting, we have shown that graft-versus-host-disease (GVHD) cannot be
induced in the absence of PKCθ. However, graft-versus-leukemia effects and T cell ability
to clear virus infection remains intact. Therefore, PKCθ is a potential therapeutic target in
BMT, inhibition of which may prevent GVHD while retaining anti-tumor and anti-infection
responses.
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Studies of PKCθ−/− mice have shown normal T cell develop-
ment but greatly impaired in vitro proliferative responses (Sun
et al., 2000; Pfeifhofer et al., 2003; Grumont et al., 2004). Several
studies have shown that PKCθ exerts functions leading to sur-
vival of T cells and activation versus tolerance outcomes in vivo
(Berg-Brown et al., 2004; Barouch-Bentov et al., 2005). In addi-
tion, PKCθ is crucial for induction of experimentally induced
autoimmunediseases inmice, including encephalomyelitis, arthri-
tis, and myocarditis (Salek-Ardakani et al., 2005; Anderson et al.,
2006; Healy et al., 2006; Marsland et al., 2007). It has also been
shown that T cells cannot mount Th2 responses in the absence of
PKCθ, while induction of Th1 responses against Leishmania major
are not substantially impacted (Marsland et al., 2004). PKCθ−/−
mice can also induce robust infection clearingCD8Tcell responses
against multiple viruses including inﬂuenza virus, LCMV, and
vaccinia virus (Marsland et al., 2004). Although in vitro prolif-
eration of PKCθ−/− T cells is typically impaired, why in vivo
responses to infectious agents remain intact is not well under-
stood. It is thought, however, that stimulation of innate immunity
by these infectious agents bypasses the requirement for PKCθ
in vivo (Marsland et al., 2005, 2007; Marsland and Kopf, 2008).
Precisely how this is accomplished and which molecular path-
ways are involved in PKCθ-independent T cell activation is not
clear. The context-speciﬁc requirement of PKCθ in T cell acti-
vation suggests that inhibition of PKCθ may be beneﬁcial in
some but not all situations. Thus, inhibiting PKCθ may be ther-
apeutically beneﬁcial, but these speciﬁc circumstances need to be
identiﬁed.
ESSENTIAL ROLE OF PKCθ IN ALLOREACTIVITY AND
GRAFT-VERSUS-HOST-DISEASE
Alloreactivity is initiated by T cells that speciﬁcally recognize
mismatched (non-self) MHC/peptide complexes. Graft-versus-
host-disease (GVHD) is a potentially lethal complication of
allogeneic bone marrow transplantation (BMT) in which allore-
active T cells from the donor are activated by mismatched major
and/or minor histocompatibility complex antigens of the recip-
ient. Although side-effects of BMT are severe, for many cancer
patients this represents a last line of hope to remove residual
tumor cells, as the alloantigen response mediating GVHD can
also promote donor T cells to exert graft-versus-leukemia (GVL)
effects (Shlomchik, 2007; Welniak et al., 2007). In this therapeu-
tic BMT procedure, GVHD is the major complication as it leads
to high morbidity and mortality of patients (Appelbaum, 2001;
Shlomchik, 2007). To date, no clinical strategy has been estab-
lished that can selectively preventGVHDwhile preserving theGVL
effect.
Given the differential requirement for PKCθ in distinct T cell-
mediated responses, we investigated a potential role for PKCθ in
the alloreactive responses of GVHD and GVL (Valenzuela et al.,
2009). To investigate thenecessity of PKCθ, weused an acutemodel
of GVHDwith thedonor and recipientmismatched for bothmajor
and minor histocompatibility complex antigens (Liang et al.,
2007). CD4 and CD8 T cells from wild-type (WT), PKCθ−/− or
NF-κB p50−/−cRel−/− mice were transferred together with WT
T cell-depleted (TCD) BM cells into lethally irradiated MHC mis-
matched recipients. p50−/−cRel−/− T cells (Zheng et al., 2003)
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were used to investigate a potential requirement for NF-κB in
this setting. As expected, recipients of WT T cells showed typ-
ical signs of GVHD with more than 70% mortality within 60
days after BMT. In a poignant divergence, the mice receiving
PKCθ−/− or p50−/−cRel−/− T cells showed little evidence of
GVHD and survived through the duration of the experiment.
Additionally, histologic analysis of the small intestine (a major
site of GVHD-induced tissue destruction) was normal in mice
receiving PKCθ−/− T cells, while their WT counterparts showed
glandular destruction, lymphocytic inﬁltrate, and loss of mucosa.
Although a clear mechanism remains elusive, additional studies
indicated that GVHD does not occur in the absence of PKCθ
because these T cells have impaired proliferation and increased
apoptosis.
PRESERVATION OF ANTI-VIRUS AND GVL RESPONSES
BY T CELLS LACKING PKCθ
Allogeneic BMT results in increased risk of life threatening infec-
tions due to conditioning regimens these patients must undergo.
Previous studies showed that responses to bacterial and viral agents
remain intact in the absence of PKCθ (Marsland et al., 2005;
Marsland and Kopf, 2008); yet, such studies have not been per-
formed in a post-BMT setting. Because CMV is one of the most
prevalent viruses carried by humans, it represents a major threat
to BMT patients (Meyers et al., 1986). To recapitulate this disease,
we used an MCMV infection model (Hossain et al., 2007, 2008).
Importantly, both anti-MCMV T cell response and virus clearance
was comparable between WT and PKCθ−/− T cell transplanted
mice (Valenzuela et al., 2009). Therefore, PKCθ is dispensable for
a successful anti-MCMV response post-BMT.
The purpose of BMT in the cancer treatment settings is for
donor T cells to be able to target malignant cells. Therefore, it is
imperative that PKCθ−/− T cells retain this GVL activity. To this
end, we performed studies (Valenzuela et al., 2009) using the A20
B cell lymphoma line (Liang et al., 2007). Different numbers of
WT and PKCθ−/− T cells were transplanted, and evaluated for
their ability to induce GVHD and mediate GVL activity. In the
absence of T cells, all recipients died from lymphoma growth. All
doses of WT T cells induced moderate to severe GVHD but little
or no lymphoma growth. In contrast, all recipients of PKCθ−/−
T cells survived through the duration of the experiment with mild
body weight loss and low GVHD. Furthermore, all the recipients
of high PKCθ−/− T cell numbers and most recipients of low or
intermediate T cell numbers remained largely free of tumor. This
result led us to the conclusion that PKCθ plays a substantial role in
the induction of GVHD, but is not essential for GVL (Valenzuela
et al., 2009). Importantly, these results indicate that pharmaco-
logical PKCθ targeting may impair GVHD without signiﬁcantly
impacting GVL responses.
KEY UNRESOLVED ISSUES IN PKCθ FUNCTION
Previous studies and our ﬁndings indicate relatively normal
responsiveness of PKCθ−/− cells to infectious agents as well as
high afﬁnity antigenic stimulation (e.g., OVA) in vivo (Valenzuela
et al., 2009). However, PKCθ−/− T cell alloreactivity and GVHD-
inducing ability is severely impaired, likely due to reduced pro-
liferation and survival in recipient mice (Valenzuela et al., 2009).
This fundamental difference in the requirement of PKCθ in various
settings is a key unanswered question, and is central for under-
standing how detrimental and beneﬁcial functions of T cells in
BMT can be separated. The speciﬁc inability of PKCθ−/− T cells
to induce GVHD can be due to several mutually non-exclusive
reasons. First, the conditioning regimen used for BMT may play
an important role. Thus, lethal irradiation prior to BMT severely
depletes recipient APC required for donor T cell activation. It is
possible that reduction in APC impacts PKCθ−/− T cell responses
more severely than WT T cells. Interestingly, allograft survival in
heart transplantation models showed a relatively small require-
ment for PKCθ in transplant rejection (Manicassamy et al., 2008;
Gruber et al., 2009), likely due to presence of compensatory func-
tions of PKCα (Gruber et al., 2009). Therefore, it is possible that
impaired alloreactivity in the absence of PKCθ ismore pronounced
in the BMT setting. Second, it is possible that defects in CD4
and CD8 T cell migration (Letschka et al., 2008) contribute to
lack of GVHD induction in the absence of PKCθ. Thus, impaired
migration of PKCθ−/− T cells to GVHD target organs such as
the gut, lungs, and skin may be responsible for reduced GVHD.
Third, the function of PKCθ in alloreactivity may not be limited
to effector T cell responses. Previous studies investigating a role
for PKCθ in Tregs suggest that PKCθ function in Treg may also
be important in alloreactivity (Zanin-Zhorov et al., 2010). While
PKCθ localizes to the immune synapse (IS) in effector T cell, PKCθ
is sequestered in a distal complex away from the IS in Treg (Zanin-
Zhorov et al., 2010). As such, PKCθ is responsible for mediating a
negative effect on the suppressive function of Treg. Consequently,
PKCθ inhibition enhances Treg function leading to protection
from inﬂammatory colitis in mice (Zanin-Zhorov et al., 2010). A
caveat worth mentioning here is that while PKCθ inhibition leads
to enhanced Treg function, PKCθ absence does not have the same
effect (Gupta et al., 2008). The underlying reason for this is not
completely clear (Zanin-Zhorov et al., 2011).
The easiest albeit simplistic way to understand why PKCθ
absence does not impact anti-infection and anti-tumor responses
is to consider a role for functionally redundant pathways. As
mentioned above, PKCθ is involved in regulating activation of NF-
κB, AP-1, and NF-AT. Studies by Marsland and colleagues have
shown that microbial stimulation through pattern recognition
receptors (PRR) can induce NF-κB activation in PKCθ−/− T cells
(Marsland et al., 2005, 2007; Marsland and Kopf, 2008). Thus,
PRR may play a key functionally redundant role with PKCθ dur-
ing infection with microbial agents. In contrast, why anti-tumor
responses are only slightly reduced in the absence of PKCθ is more
difﬁcult to understand. BMT is primarily used for leukemia treat-
ment. Leukemic cells, in particular B lymphocytes, have naturally
high expression of MHC and co-stimulatory molecules, reﬂecting
the natural function of these lineages in antigen presentation. In
the above-mentioned study (Valenzuela et al., 2009), A20 B cell
lymphoma cells were used as tumor targets. Whether PKCθ−/−
T cells are speciﬁcally (or only) able to eradicate leukemic tumors
can be directly tested by determining PKCθ requirement in erad-
ication of non-leukemic tumors. Mechanistically, one possibility
is that functionally redundant pathways are strongly activated in
PKCθ−/− T cells by A20 and potentially other leukemic tumors.
Furthermore, leukemic tumors may represent better targets for
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PKCθ−/− T cells than epithelial cells targeted during GVHD.
Regardless of precise mechanisms, it is likely that both responses
to infectious agents and leukemic tumors are maintained in the
absence of PKCθ through functionally redundant pathways. A
recent study identiﬁed anovel role forPKCθ as a transcriptional co-
activator capable of interacting with promoters of several immune
function genes (Sutcliffe et al., 2011). How this function impacts
alloreactivity and other known functions for PKCθ remains to be
determined.
INVESTIGATING THE EFFECT OF PKCθ INHIBITION
IN GVHD AND GVL
The above-mentioned studies provide strong rationale for target-
ing PKCθ in a BMT settings (Valenzuela et al., 2009). The PKC
family has been implicated in tumor cell proliferation, survival,
invasion, metastasis, and tumor angiogenesis. Therefore, tar-
geting PKC isotypes may present an attractive target for novel
anticancer therapies. Consequently, several inhibitors of PKC
isoforms have been developed by different pharmaceutical compa-
nies. Although some selective PKCθ inhibitors have been reported
(Cywin et al., 2007; Cole et al., 2008), their in vivo toxicity or efﬁ-
cacy remains to be determined. A major advance was achieved
recently with AEB071 (developed by Novartis), a very potent
and selective inhibitor of both novel and classical PKCs. Skvara
et al. (2008) reported that treatment with AEB071 signiﬁcantly
improved symptoms of patients with severe psoriasis. Another
potentially important PKC inhibitor is enzastaurin (Ly317615,
from Eli Lilly and Company; Baier and Wagner, 2009). Enzas-
taurin was identiﬁed as an inhibitor of the PKCβ isoform, but it
also impacts the AKT pathway (Graff et al., 2005); importantly,
enzastaurin inhibits the PKCθ isoform approximately ﬁvefold
more potently than the beta isoform (Graff et al., 2005). In vivo
studies indicate that enzastaurin is very well tolerated with a
favorable safety proﬁle, allowing it to be dosed for extended
durations (Herbst et al., 2007). Furthermore, enzastaurin has anti-
proliferative and pro-apoptotic activity in solid tumors as well as
hematological malignancies, including leukemia and lymphoma
(Herbst et al., 2007). Thus, while not exclusively speciﬁc for PKCθ,
enzastaurin has the major advantage of being well tolerated in
vivo and the added beneﬁt of anti-tumor effects. Hence, PKCθ
inhibition by enzastaurin may prevent GVHD while preserving
GVL responses, which will act cooperatively with the direct anti-
tumor effects of enzastaurin. We expect future studies to deﬁne
more potent and speciﬁc inhibitors of PKCθ and consequently
help move this important therapeutic target to the clinical arena.
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